Patents Represented by Attorney, Agent or Law Firm Lisa A. Haile
-
Patent number: 6806048Abstract: Disclosed is a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nucleic acid directly isolated from the environment; and (ii) screening said libraries utilizing a fluorescence activated cell sorter to identify said clones. More particularly, this is a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a fluorescence activated cell sorter to identify clones which react with the substrate or substrates.Type: GrantFiled: May 3, 2001Date of Patent: October 19, 2004Assignee: Diversa CorporationInventors: Jay M. Short, Martin Keller
-
Patent number: 6794127Abstract: Provided are methods of screening and identification of bio activities and bioactive molecules of interest using a capillary array system. More specifically, disclosed are methods of using optical detection and capillary array-based techniques for screening libraries and recovering bioactive molecules having a desired activity or a nucleic acid sequence encoding such bioactive molecules.Type: GrantFiled: October 12, 2000Date of Patent: September 21, 2004Assignee: Diversa CorporationInventors: William Michael Lafferty, Jay M. Short, Martin Keller
-
Patent number: 6764683Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF&agr;, was discovered as having TGF&agr; biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF&agr; polypeptide. There is further disclosed that TGF&agr; and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.Type: GrantFiled: December 13, 1999Date of Patent: July 20, 2004Assignee: Kaleidos Pharma, Inc.Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
-
Patent number: 6746867Abstract: The invention relates to a family of mammalian genes that are transcribed in the immediate early phase following exposure to Fibroblast Growth Factors (FGF) during mesoderm induction, termed Mesoderm Induction Immediate Early Response (MIER) genes. Defining features of the members of this family include that these genes are a) transcribed in response to fibroblast growth factors (FGF); b) are expressed within 40 minutes of FGF treatment; and c) do not require protein synthesis for transcription. There are at least eleven members within this family. The invention relates generally to compositions of and diagnostic methods relating to the M-MIER gene family, cDNA, nucleotide fragments, polypeptides coded thereby, recombinant host cells and vectors containing M-MIER encoding polynucleotide sequences, recombinant M-MIER polypeptides, and antibodies. By way of example, the invention discloses the cloning and functional expression of different M-MIER polypeptides.Type: GrantFiled: October 13, 1998Date of Patent: June 8, 2004Assignee: Genesis Group Inc.Inventors: Laura Lee Gillespie, Gary David Paterno
-
Patent number: 6733971Abstract: The present invention provides transcription factors associated with the hedgehog signaling pathway that are regulated by dephosphorylation by phosphatases. Hedgehog response elements (HRE) that interact with the dephosphorylated transcription factors are also provided as well as methods for identifying compounds that are phosphatase inhibitors. Methods of treating tumors in a subject by modulating the phosphorylation of the transcription factor are also included.Type: GrantFiled: August 21, 2001Date of Patent: May 11, 2004Assignees: Baylor College of Medicine, The Johns Hopkins University School of MedicineInventors: Philip A. Beachy, Ming-Jer Tsai, Sophia Tsai, Venkatesh Krishnan, Chien-Huan Chen
-
Patent number: 6720145Abstract: Disclosed is a method for removing polynucleotide from the skin. This polynucleotide can be used to detect dermatitis and distinguish an irritant reaction from an allergic reaction by characterizing the polynucleotide according to the polypeptide which it encodes. Additionally, provided are methods for non-invasive isolation of samples from the skin as well as kits for use in the methods provided herein.Type: GrantFiled: September 28, 2001Date of Patent: April 13, 2004Assignee: Dermtech InternationalInventors: Lawrence A. Rheins, Vera B. Morhenn
-
Patent number: 6720175Abstract: A method is provided for identifying a compound that modulates a cellular response associated with Homer and mediated by a cell-surface or an intracellular receptor. A method is further provided for identifying a compound that modulates receptor activated calcium mobilization associated with Homer. A method is provided for identifying a compound that inhibits Homer protein activity based on the crystal structure coordinates of Homer protein binding domain. A method is also provided for identifying a compound that affects the formation of cell surface receptors into clusters. Also provided are nucleic acids encoding Homer proteins as well as Homer proteins, and Homer interacting proteins.Type: GrantFiled: August 18, 1999Date of Patent: April 13, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Paul F. Worley, Jian Cheng Tu, Bo Xiao, Daniel Leahy, Jutta Beneken, Anthony A. Lanahan, Paul R. Brakeman
-
Patent number: 6716825Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorder, e.g., osteoporosis and other disorders of bone metabolisum, cancer, viral infections, and the like.Type: GrantFiled: November 6, 2002Date of Patent: April 6, 2004Assignee: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, James R. Beadle, Ganesh D. Kini
-
Patent number: 6713302Abstract: Growth differentiation factor-6 (GDF-6) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-6 polypeptide and polynucleotide sequences.Type: GrantFiled: July 18, 2000Date of Patent: March 30, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Thanh Huynh
-
Patent number: 6709818Abstract: Provided are methods and compositions useful for the diagnosis, prognosis and treatment of hepatic cellular proliferative disorders. The methods include the modulation or analysis of hypemethylated glutathione-S-transferase nuleic acid sequence in hepatic samples and biological fluids.Type: GrantFiled: October 12, 2000Date of Patent: March 23, 2004Assignee: The Johns Hopkins University School of MedicineInventors: William G. Nelson, Xiaohui Lin, Julia C. Tchou, Jila Bakker
-
Patent number: 6706509Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.Type: GrantFiled: May 18, 2001Date of Patent: March 16, 2004Assignee: The Regents of the University of CaliforniaInventors: Michael Karin, Masahiko Hibi, Anning Lin
-
Patent number: 6706498Abstract: The invention describes a method for the isolation of components from samples, particularly large molecular weight DNA from biological samples. The method involves the application of controlled oscillatory mechanical energy to the sample for short periods of time of about 5 to 60 seconds to lyse the sample and release the component(s) from the sample, followed by standard isolation methods. In preferred embodiments, the method includes the use of a spherical particle for applying the mechanical energy.Type: GrantFiled: May 22, 2001Date of Patent: March 16, 2004Assignee: Bio101, Inc.Inventors: James W. Gautsch, Michael G. Saghbini, David A. Lippman, Richard C. Dana
-
Patent number: 6699660Abstract: The present invention provides methods and materials related to immediate early genes. Specifically, the invention provides isolated immediate early gene nucleic acid, cells that contain isolated immediate early gene nucleic acid, substantially pure polypeptides encoded by immediate early gene nucleic acid, and antibodies having specific binding affinity for a polypeptide encoded by immediate early gene nucleic acid. In addition, the invention provides cDNA libraries enriched for immediate early genes cDNAs, isolated nucleic acid derived from such cDNA libraries, and methods for treating conditions related to a deficiency in a neuron's immediate early gene responsiveness to a stimulus.Type: GrantFiled: February 5, 1999Date of Patent: March 2, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Paul F. Worley, Anthony Lanahan, Bernhard Goetz, Holger Hiemisch, Rohini Kuner, Sigrid Scheek, Karoly Nikolich, Eugene Zhukovsky
-
Patent number: 6699482Abstract: The present invention presents novel leptospiral membrane lipoproteins, LipL1 and LipL2, associated with pathogenic strains of Leptospira. LipL1 is of about 35 kDa, and LipL2 is of about 41 kDa. Also disclosed are the method for purifying these proteins from Leptospira, their nucleotide and amino acid sequences, the cloning of the genes encoding the proteins and their recombinant proteins, methods for producing antibodies to these proteins, the resulting antibodies. These proteins, their immunogenic fragments, and antibodies against them, are useful for inducing an immune response to pathogenic Leptospira as well as providing a diagnostic target for leptospirosis.Type: GrantFiled: November 13, 2001Date of Patent: March 2, 2004Assignee: The Regents of the University of CaliforniaInventors: David A. Haake, Ellen S. Shang
-
Patent number: 6696260Abstract: The present invention provides receptors for the growth differentiation factor (GDF) family of growth factors and methods of identifying such receptors. Also included are methods of identifying antibodies which bind to the receptors, peptide fragments of the receptor which inhibit GDF binding, GDF receptor-binding agents capable of blocking GDF binding to the receptor. The receptors of the invention allow the identification of antagonists or agonists useful for agricultural and human therapeutic purposes.Type: GrantFiled: May 5, 2000Date of Patent: February 24, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra McPherron
-
Patent number: 6696559Abstract: Novel antimicrobial peptides from bovine and murine neutrophils are provided. The peptides, designated bovine granulocyte peptide A (BGP-A) and murine granulocyte peptide A (MGP-A) were purified to homogeneity from peripheral blood granulocytes. The amino acid and nucleotide sequence of BGP-A and MGP-A are also provided. A synthetic version of BGP-A and MGP-A is also provided. The purified BGP-A peptide is shown to have antimicrobial activity indistinguishable from that of natural BGP-A. Synthetic carboxamidated analogs of BGP-A (BGP-A-amide) and MGP-A (MGP-A-amide) are also provided.Type: GrantFiled: October 19, 1999Date of Patent: February 24, 2004Assignee: The Regents of the University of CaliforniaInventor: Michael E. Selsted
-
Patent number: 6685945Abstract: An antigenic preparation is provided which contains a 31 Kd outer membrane protein from Leptospira which can be used immunologically as a vaccine for leptospirosis caused by this organism.Type: GrantFiled: August 19, 1997Date of Patent: February 3, 2004Assignee: The Regents of the University of CaliforniaInventors: David A. Haake, David R. Blanco, Cheryl I. Champion, Michael A. Lovett, James N. Miller
-
Patent number: 6686458Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.Type: GrantFiled: April 19, 2002Date of Patent: February 3, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, B. Albert Griffin
-
Patent number: 6682904Abstract: Methods for identifying a hyaluronidase 2 (HYAL2) specific inhibitor, which selectively inhibits HYAL2 activity, but does not substantially affect the activity of non-inflammatory hyaluronidases, are provided. Also provided are HYAL2 specific inhibitors obtained using such a method. In addition, methods for ameliorating an inflammatory disorder or vasculitis condition by specifically inhibiting HYAL2 is provided.Type: GrantFiled: August 15, 2002Date of Patent: January 27, 2004Assignee: Deliatroph Pharmaceuticals, Inc.Inventor: Gregory I. Frost
-
Patent number: 6680372Abstract: The present invention provides antibodies that bind to the growth differentiation factor-7.Type: GrantFiled: October 5, 1999Date of Patent: January 20, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Thanh Huynh